Loading news...
Superstring Capital Management reduced its stake in Terns by 345,869 shares during the fourth quarter; the estimated trade value was $7.99 million based on quarterly average prices. Meanwhile, the quarter-end position value declined by approximately $12.00 million, reflecting both trading and stock price movements.
Vestal Point acquired 4,500,000 shares of Terns Pharmaceuticals in the fourth quarter. The quarter-end position value increased by $181.80 million as a result of this purchase, which created a new stake for the fund.
Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) was the target of unusually large options trading on Friday. Traders bought 9,767 call options on the stock. This represents an increase of 501% compared to the typical volume of 1,624 call options. Terns Pharmaceuticals Price Performance NASDAQ: TERN opened at $46.52 on Friday. The business has a
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position TERN, ADMA, ANIP and LQDA in this volatile sector.
Dynamic Technology Lab Private Ltd increased its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ: TERN) by 237.2% in the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,576 shares of the company's stock after purchasing an additional 46,831 shares during the quarter. Dynamic Technology Lab
Why momentum investing often outperforms buy-and-hold - and how stage analysis identifies breakout stocks early.
DLD Asset Management LP cut its holdings in Terns Pharmaceuticals, Inc. (NASDAQ: TERN) by 73.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,000 shares of the company's stock after selling 27,047 shares during the quarter. DLD Asset
Stock market volatility is rising as algorithms react instantly to global events, forcing investors to rethink traditional strategies.
New position: 375,000 shares added; estimated trade size ~$15.15 million based on quarterly average price Quarter-end position value increased by $15.15 million, reflecting both trading activity and stock price movement Position accounts for a 3.32% change in Boxer Capital's 13F reportable assets under management Post-trade holding: 375,000 shares valued at $15.15 million TERN enters Boxer Capital's portfolio as a new position but is not among the fund's top five holdings
AI is driving a massive stock market rotation. Why software stocks are falling - and hard assets are suddenly winning.
FOSTER CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be participating in the following upcoming investor conferences in March.
ORBIMED Advisors LLC reduced stake by 5,409,671 shares in Terns Pharmaceuticals; the estimated trade size is $125.01 million based on quarterly average price Quarter-end position value decreased by $30.20 million, reflecting both trading and share price movement Transaction represented 2.55% of fund's 13F reportable AUM Post-trade position: 2,153,300 shares, valued at $86.99 million Stake now makes up 1.78% of fund AUM, placing it outside the fund's top five holdings These 10 Stocks Could Mint the Next Wave of Millionaires ›
Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has issued a strong buy rating
First Turn Management acquired 872,049 shares in Terns Pharmaceuticals during the fourth quarter. The quarter-end Terns Pharmaceuticals position value increased by $35.23 million, reflecting both the new stake and stock price movements.
The consensus price target hints at a 50.9% upside potential for Terns Pharmaceuticals (TERN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FOSTER CITY, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of February 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended.
Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CARDINAL Phase 1/2 trial of TERN-701 enrolling well, with multiple important milestones in 2026 Planned milestones include pivotal dose selection, EOP2 regulatory interaction in mid-2026, updated and expanded CARDINAL data by 2H26, and initiation of 2L+ pivotal trial in late 2026/early 2027 TERN-701 was granted U.S. FDA Fast Track designation for the treatment of CML in Q4 2025 Year-end 2025 unaudited cash, cash equivalents and marketable securities of approximately $1.0 billion, expected to provide runway into 2031 FOSTER CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that management will provide an update on 2026 priorities and program milestones during the Company's presentation at the 44th Annual J.P.
FOSTER CITY, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted as of January 1, 2026 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended.
Amy Burroughs, Terns Pharmaceuticals CEO, joins 'Fast Money' to talk its latest cancer drug data